�Pfizer Inc said that the Eastern Division of the High Court in Copenhagen, Denmark has ruled in the company's favour in challenges to two of its patents covering atorvastatin, the active factor in Lipitor. The basic (DK 171,588) and enantiomer (EP 409,281) patents were challenged by generics manufacturer Ranbaxy.
The court ruled that the basic patent, which expires in November 2011, would be infringed by Ranbaxy's generic atorvastatin product. The court as well ruled that the atovastatin enantiomer patent is valid. That patent expires in July 2010. The conclusion, which is subject to possible appeal, prevents Ranbaxy from entry its generic product in front November 2011.
"Today's conclusion is an important result for Pfizer and other medical innovators who endue in bad research to develop lifesaving medicines for millions of patients," aforesaid Pfizer Denmark Country Manager Karin Verland.
http://www.pfizer.com
More info
Subscribe to:
Posts (Atom)